RxDoctor Payments Data

Garima Methi

Family Medicine · Maumee, OHNPI 1679006415

Payments from drug & device makers

$1,640in general payments, 2019–2025

Across 124 payments — averaging $13.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$378
  • Novo Nordisk$375
  • Pfizer$240
  • Biohaven Pharmaceutical Holding Company Ltd.$67
  • Lilly USA, LLC$66
  • Boehringer Ingelheim$53
  • plus $460 from 18 others

What the payments were for

  • Food & beverage$1,640100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,640 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$56,906
Medicare patients
160
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide197$223,722
FarxigaDapagliflozin Propanediol100$80,605
JardianceEmpagliflozin72$70,288
MounjaroTirzepatide57$67,137
TrulicityDulaglutide55$67,098
EliquisApixaban69$51,961
RybelsusSemaglutide21$31,294
XareltoRivaroxaban23$21,022
WegovySemaglutide14$19,031
JanuviaSitagliptin Phosphate16$18,428
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,291
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$15,403
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$13,845
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$10,268
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$10,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$375$274,047232 claims
Lilly USA, LLCMounjaro, Trulicity$66$134,235112 claims
AstraZenecaFarxiga, Breztri Aerosphere$43$94,450118 claims
Boehringer IngelheimJardiance$53$70,28872 claims
PfizerEliquis, Premarin$240$54,09984 claims
GSKTrelegy Ellipta, Anoro Ellipta$13$27,41129 claims
Johnson & JohnsonXarelto$36$21,02223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Maumee

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →